Managing Pretreated Metastatic Colorectal Cancer - priME Oncology
Clinical Spotlight
Clinical Spotlight

Managing Pretreated Metastatic Colorectal Cancer

Updates From the 2018 Gastrointestinal Cancers Congress in Barcelona

Not a member of My prIME? Join now for instant access.

Update your treatment options for metastatic colorectal cancer (mCRC) via this thought leader discussion and related slide deck. This activity features valuable updates and expert perspectives on exciting new developments in the management of mCRC released at the 2018 Gastrointestinal Cancers Congress in Barcelona.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

CME

CME

0.5 AMA PRA Category 1 Credits™

Release Date

Release Date

Jun 29, 2018

Expiration Date

Jun 29, 2019

Fine-Tuning the Landscape of Refractory Metastatic Colorectal Cancer

Featured Experts

  • Tanios Bekaii-Saab, MD, FACP, Mayo Clinic, Phoenix, Arizona, United States
  • Alberto Sobrero, MD, Ospedale San Martino, Genova, Italy

Featured Abstracts

Abstract #O-012: Safety and effectiveness of rego in patients with metastatic colorectal cancer (mCRC) in routine clinical practice: Final analysis from the prospective, observational CORRELATE study

Abstract #O-013: Safety and efficacy of TAS-102 in previously treated metastatic colorectal cancer (mCRC): Preliminary results from the phase IIIb, international, open-label, early-access PRECONNECT study

Abstract #O-014: Rego Dose Optimization Study (ReDOS): Randomized phase II trial to evaluate escalating dosing strategy and pre-emptive topical steroids for rego in refractory metastatic colorectal cancer (mCRC) – An ACCRU Network study

Immunotherapy for Advanced Metastatic Colorectal Cancer

Featured Experts

  • Tanios Bekaii-Saab, MD, FACP, Mayo Clinic, Phoenix, Arizona, United States
  • Alberto Sobrero, MD, Ospedale San Martino, Genova, Italy

Featured Abstracts

Abstract #LBA-004: Efficacy and safety results from IMblaze370, a randomized Phase III study comparing atezo plus cobi and atezo monotherapy vs. rego in chemotherapy-refractory metastatic colorectal cancer

Abstract #O-021: Safety and antitumor activity of pembro in patients with advanced microsatellite instability–high (MSI-H) colorectal cancer: KEYNOTE-164

Featured Experts

  • Tanios Bekaii-Saab, MD, FACPMayo Clinic
    Phoenix, Arizona, United States
  • Alberto Sobrero, MDOspedale San Martino
    Genova, Italy

The information in this activity is intended for gastroenterologists, medical oncologists, and other healthcare professionals involved in the management of CRC.

After successful completion of this educational activity, participants should be able to:

  • Evaluate treatment options for previously treated mCRC, including new data on the use of targeted therapy in real-world settings and the role of immunotherapy in mCRC
  • Select patients for treatment using tyrosine kinase inhibitors and supportive care measures to optimize outcome and minimize toxicity

This educational activity is supported by a grant from Bayer HealthCare Pharmaceuticals, Inc.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

prIME Oncology designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the Terms of Use.

Links to the posttest are available on the video player pages.

In order to receive credit, participants must successfully complete the online posttest with 75% or higher.

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Bekaii-Saab has disclosed that he has received consulting fees from AbbVie, Armo Biosciences, Exelixis, Merck, and Silagen. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Sobrero has disclosed that he has received consulting fees from Bayer HealthCare Pharmaceuticals, Inc. and Servier. He has received honoraria for promotional speaker’s bureaus from Bayer HealthCare Pharmaceuticals, Inc.; Merck; Roche; Sanofi; and Servier. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Bojana Pajk, MD (medical director content reviewer/planner) – no relevant financial relationships
  • Sanneke Koekkoek, RN (scientific content reviewer/planner) – no relevant financial relationships
  • Jessica Mastrodomenico, MPH (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.